CD40LG and neoplasm: The introduction of pro-inflammatory cytokines (currently mainly IL-12) and co-stimulatory ligands (4-1BBL and CD40L) has reduced the incidence of adverse effects during pretreatment therapy and elicited a wider range of anti-tumor immune effects (38).